User:Mr. Ibrahem/Olutasidenib
 | |
| Clinical data | |
|---|---|
| Trade names | Rezlidhia |
| Other names | FT-2102 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | By mouth |
| Drug class | IDH1 inhibitor[1] |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C18H15ClN4O2 |
| Molar mass | 354.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Olutasidenib, sold under the brand name Rezlidhia, is an medication used to treat acute myeloid leukemia.[1] Specifically it is used in those with certain IDH1 mutations who have failed other treatments.[1] It is taken by mouth.[1]
Common side effects include nausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, and diarrhea.[1] Common lab abnormalities include high potassium, low sodium, liver problems, and kidney problems.[1] Other side effects may include differentiation syndrome.[1] It is an isocitrate dehydrogenase-1 (IDH1) inhibitor.[1]
Olutasidenib was approved for medical use in the United States in 2022.[1] In the United States it costs about 32,200 USD per month as of 2022.[4]
References[edit]
- ^ a b c d e f g h i j k l "REZLIDHIA™ (olutasidenib) capsules, for oral use". Archived from the original on 15 January 2023. Retrieved 15 January 2023.
- ^ "Archive copy" (PDF). Archived (PDF) from the original on 2022-12-13. Retrieved 2022-12-20.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215814Orig1s000ltr.pdf Archived 2022-12-20 at the Wayback Machine
This article incorporates text from this source, which is in the public domain.
- ^ "Optum Rx Revenue Grows 9% in 2022". Formulary Watch. Archived from the original on 15 January 2023. Retrieved 15 January 2023.
